Introduction
Macrophage-stimulating protein (MSP, also known as hepatocyte growth factor like protein, HGFL) is a plasminogen-like growth factor that mediates its biological activities by activating the receptor tyrosine kinase RON (recepteur d'origine nantaise, also known as macrophage stimulating receptor-1, MSTR1), a member of the METproto-oncogene family (1) . MSP shares high sequence and structural domain homology with hepatocyte growth factor (HGF), the ligand for MET; similarly, their respective cognate receptors, RON and MET, also share high sequence and domain homology (2) .
The α-chain of MSP consists of an N-terminal PAN module followed by four Kringle domains and is disulfide-linked to the trypsin-like β-chain (3). MSP is constitutively expressed by hepatic parenchymal cells, as well as in lungs, adrenal glands, placenta, kidney and pancreas (4, 5) . It is secreted as an inactive single-chain precursor pro-MSP, which requires proteolytic cleavage at the Ser-Lys-Leu-Arg bond results in distinct structural rearrangements within the HGF β-chain and the formation of a MET binding site that is competent for signal transduction (7) (8) (9) . Comparable conformational rearrangements centered at the 'pseudo-active site' in the MSP β-chain are likely to occur upon activation cleavage of pro-MSP (7). However, unlike HGF, where the high affinity MET binding site resides in the α-chain, the high affinity RON binding site for MSP is located on the mature β-chain that forms following pro-MSP cleavage (10) . Several trypsin-like serine proteases, including MT-SP1 (also known as matriptase) and HGF activator (HGFA) (11) (12) (13) (14) (15) are known to activate pro-MSP, leading to typical cellular responses mediated by the RON signaling pathway (11, 12) .
Hepsin is a cell surface-expressed trypsin-like protease and a member of the type II transmembrane serine protease family (16, 17) . It consists of a N-terminal cytoplasmic domain, a transmembrane domain and an extracellular portion composed of a scavenger receptor-like cysteine-rich domain and a C-terminal protease domain with a trypsin-like fold (18, 19) . Hepsin was identified as one of the most highly upregulated genes in prostate cancer (20) (21) (22) (23) (24) (25) and immunohistochemical staining revealed strong expression in late stage tumors and metastatic bone lesions (26, 27) . Studies with preclinical prostate cancer models suggested that hepsin may play a role in invasive cancer growth and cancer progression (28, 29) . Moreover, gene expression analyses have also implicated hepsin in ovarian cancer (30) , renal cell carcinoma (31, 32) and endometrial cancer (33) .
A putative function of hepsin in tumor progression could be related to its enzymatic activity towards the macromolecular substrates pro-HGF (19, 34) , pro-uPA (35) and laminin-332 (36) . Additional substrates that have been identified are coagulation factors (37) and pro-prostasin (38) . The hepsin cleavage sequences of these substrates are in good agreement with the consensus sequence obtained from substrate profiling by positional scanning of a synthetic combinatorial peptide library (19) .
Here we report that both recombinant soluble hepsin (sHepsin) and cell surfaceexpressed hepsin efficiently cleave human pro-MSP at the physiological activation site. 
Materials and Methods

Cloning, expression and purification of recombinant proteins
The extracellular domain of the human recombinant hepsin harboring a C-terminal Histag (sHepsin) was expressed and purified as described (35) in Chinese Hamster Ovary (CHO) cells. RON-Fc was purified by affinity chromatography followed by size-exclusion chromatography. Recombinant pro-MSP harboring a C-terminal His 6 tag along with a C672A mutation, previously shown to yield better protein expression, was expressed in CHO cells as described (39) . Secreted pro-MSP was purified by Ni-NTA affinity chromatography followed by size-exclusion chromatography on Superdex-S200 column. Most of the MSP present in the pro-MSP preparation was removed by incubation with RON-Fc followed by a protein-A column purification and pro-MSP was collected in the flow-through (Suppl. Fig. S1A and Fig.   1A ). To generate a non-activatable form of pro-MSP the P1 residue Arg483 was mutated to Glu (scMSP) using Quikchange mutagenesis (Stratagene). Thus, scMSP actually contains two mutations: R483E and C672A. The protein was expressed and purified as derived from HGF activator inhibitor type-1 (HAI-1) were expressed and purified as described (40, 41) . Recombinant active human MSP was obtained from R & D Systems and used as reference material. Antibody25 (Ab25) inhibits hepsin enzymatic activity and was generated by using antibody phage display. Ab25 (IgG1) and Fab25 were expressed in CHO cells and E. coli, respectively and were purified according to standard procedures.
In vitro activation of pro-MSP by sHepsin, HGFA and sMT-SP1
Pro-MSP (100 μg/ml = 1.25 μM) was incubated for 1 h at 37°C with different concentrations (100 nM -97 pM, 2-fold dilution series) of sHepsin, HGFA and sMT-SP1 in a buffer containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05% Triton-X100 and 2 mM CaCl 2 for 1 h at 37°C. In addition, 100 nM of the proteases were pre-incubated for 15 µg/ml of the scMSP mutant and hepsin (10 nM). For the densitometric analysis of pro-MSP degradation, the pro-MSP band intensities were quantified using ImageJ from the National Institutes of Health (http://rsb.info.nih.gov/ij/index.html). The effective concentration to give 50% reduction (EC 50 ) was determined by a four parameter fit (Kaleidagraph, Synergy Software, Reading, PA).
sHepsin-cleaved MSP was prepared by incubating 100 µg/ml of pro-MSP with 15 nM sHepsin for 1 h resulting in complete conversion to cleaved MSP. sHepsin was removed by adding molar excess of anti-hepsin Ab25 to the reaction mixture followed by Protein A-Sepharose chromatography. Thus purified MSP did not contain any residual hepsin as assessed by SDS-PAGE and enzymatic assays. A similar protocol was used to generate HGFA-cleaved MSP except that the anti-HGFA antibody Ab40 (42) was used to remove HGFA from the reaction mixture.
Pro-MSP activation by cell surface expressed hepsin on LNCaP-34 cells
LNCaP-34 cells stably overexpressing human full-length hepsin were described previously (35) . Confluent cultures in 24-well plates were incubated for 15 min at 37°C with 500 µl serum-free RPMI-1640 medium containing 1µM each of Ab25 or KD1 or Ac-KQLR chloromethyl ketone (Ac-KQLR-cmk; Anaspec, San Jose, CA) or 10 nM sHepsin.
125
I-labeled pro-MSP, prepared as described for pro-HGF (34), was added (25 μg/ml) and incubated for 3 h at 37°C. Aliquots were analyzed by SDS-PAGE (4-20% gradient gel) followed by exposure to X-ray films. The intensities of the bands were quantified using ImageJ software. The loss of pro-MSP band intensity was used to determine the percentage of proteolytic activity. 
Inhibition of NO synthesis by mature MSP
Bone marrow cells were isolated from femurs of C57BL/6 mice as described (11) .
After washing the cell suspension with DMEM, red blood cells were lysed with erythrocyte lysis buffer. Cells were resuspended in macrophage differentiation medium (DMEM with glutamine, 10% FBS, 1X Pen/Strep and 50 ng/ml mCSF-1) and added to 24-well plates. Medium was changed the next day and subsequently every second day.
After 6 days the matured macrophages were incubated for 24 h at 37°C in 300 µl/well of serum-free medium with or without 1 µg/ml of lipopolysaccharide (LPS) (Sigma) and containing: (a) 10 ng/ml pro-MSP, (b) 10 ng/ml pro-MSP and 1 nM sHepsin, (c) 10 ng/ml pro-MSP, 1 nM sHepsin and 500 nM Ab25, (d) 10 ng/ml MSP (R&D). NO production was quantified by measuring the concentration of nitrite in diluted aliquots of culture medium by use of the Griess reaction kit (Molecular Probes). 
Phosphorylation of signaling proteins downstream of RON
Computational gene expression analysis
Microarray data on the Affymetrix HG-U133A and HG-U133B GeneChips were obtained from the GeneLogic (Gaithersburg, MD) database. We extracted samples that were classified as normal or as having non-cancer disease, and used the signal intensity values from the Microarray Analysis Suite version-5 software. We used the following microarray probes to measure gene expression: MSP, 205614_x_at; Hepsin, 204934_s_at; HGFA, 207027_at; MT-SP1, 202005_at; and RON, 205455_at. For each tissue type, we generated expression profiles to show the mean and standard deviation of gene expression values. For the four tissue types having the highest mean expression of MSP, liver, kidney, pancreas, and small intestine, we generated scatter plots to show the relations of expression of MSP against that of other genes. All plots were generated using the R statistical package. (43)) consensus sequence (19) , which is in good agreement with the identified cleavage site sequences from macromolecular substrates of hepsin (34-37) ( Table 1 ). The consensus sequence and particularly the specific hepsin recognition sequences of laminin-332 (SQLR↓L) and pro-HGF (KQLR↓V) bear a close resemblance to the cleavage sequence of pro-MSP (SKLR↓V). Therefore, we hypothesized that hepsin could be a pro-MSP activator. To examine this hypothesis we expressed pro-MSP in Chinese
Results
In vitro activation of pro-MSP by recombinant hepsin
Hamster Ovary (CHO) cells, but found it partially converted into the 2-chain form (MSP). Since, MSP but not pro-MSP binds to its receptor RON, we further purified pro-MSP by incubating it with RON-Fc for 16 h at 4°C followed by an affinity chromatographic purification step. The resulting pro-MSP was of high purity and contained only small amounts of activated MSP (Suppl. We compared the enzymatic activity of sHepsin with the two known pro-MSP converting proteases sMT-SP1 and HGFA. sHepsin, sMT-SP1 and HGFA cleaved pro-MSP in a concentration-dependent fashion and their activities were completely inhibited by KD1, the N-terminal Kunitz domain of their physiologic inhibitor HAI-1 (Fig. 1A) .
The anti-hepsin antibody Fab25 specifically inhibited pro-MSP processing by sHepsin, but not by sMT-SP1 or HGFA (Fig. 1A) . The relative pro-MSP converting potencies of the three proteases were quantified by measuring the disappearance of the pro-MSP band by densitometry. The results showed that sHepsin (EC 50 = 2.4 ± 0.3 nM) was 5-fold and 7-fold more efficient than sMT-SP1 (EC 50 = 11.7 ± 1.3 nM) and HGFA (EC 50 
Pro-MSP activation by cell surface-expressed hepsin
To determine pro-MSP processing by cell surface-expressed full-length hepsin, we used the prostate cancer cell line LNCaP-34, which was engineered to stably overexpress hepsin on the cell surface (35) . Incubating LNCaP-34 cells with 125 I-labeled pro-MSP over a 3 h period showed that >80% of pro-MSP was converted to the twochain α/β heterodimer form. The effect is similar to what was observed when pro-MSP was treated with 10 nM sHepsin in the LNCap cell cultures (Fig. 1B) , which resulted in >92% conversion of pro-MSP compared to the pro-MSP only control (lane1). Cleavage of pro-MSP was inhibited by three different inhibitors -KD1, which inhibits hepsin, MT-SP1, and HGFA (40), KQLR-cmk, an irreversible peptide inhibitor mimicking the pro-HGF cleavage sequence KQLR↓V (19, 44) , and Ab25 (Fig. 1B) . While KD1 and KQLRcmk and are not selective inhibitors, the inhibition observed for them is similar that for the selective hepsin inhibitor Ab25. Thus any activation by other proteases, in particular MT-SP1 that is present on LNCaP-34 cells (35) , is minimal.
Binding of sHepsin-cleaved MSP to RON
Cleavage of pro-MSP at the Arg (Fig. 3A, B) . However, co-incubation of A2780 cells with pro-MSP and sHepsin resulted in robust phosphorylation of RON, MAPK, S6, and Akt to levels that were comparable to treatment with active MSP (Fig. 3A,B) . Furthermore, siRNA-mediated suppression of RON expression completely attenuated the phosphorylation of these downstream signaling molecules suggesting that the effect was mediated through RON (Suppl. Fig.   S2 ).
Peritoneal macrophage morphology change and chemotaxis assay
MSP induces mouse resident peritoneal macrophages to assume a more flat and spread-out morphology similar to what is seen with other chemo-attractants (6, 45) . Therefore, we examined whether processing of pro-MSP by sHepsin produced an active MSP capable of eliciting these responses. sHepsin-cleaved MSP was added to primary mouse peritoneal macrophages in culture. After 1 h incubation, peritoneal macrophages treated with MSP/sHepsin, underwent distinct changes in cell shape, assuming a flat morphology with elongated protrusions (Fig. 3C) , unlike the cells treated with pro-MSP alone, which had a more spherical morphology. The effect of sHepsin-activated MSP was comparable with that of the MSP from a commercial source. No cell shape changes were observed in the medium control or with the addition of scMSP or sHepsin (Fig. 3C) . However, weak morphological changes were observed in pro-MSP control wells, perhaps due to baseline activation of pro-MSP by some of the known pro-MSP activators like MT-SP1, which are also expressed in macrophages (11) .
In addition, macrophages were co-incubated with pro-MSP and sHepsin, which resulted in a significant increase (p<0.001) in peritoneal macrophage migration (Fig. 4A) that was comparable to MSP from a commercial source. The pro-migratory effect was due to the generation of active MSP by sHepsin, since neither pro-MSP nor uncleavable scMSP by themselves increased cell migration (Fig. 4A ). In accord with this, the addition of hepsin neutralizing antibody (Ab25) completely inhibited the increased pro-migratory activity found with pro-MSP and sHepsin (Fig. 4A) .
Inhibition of nitric oxide synthesis
In epithelial cells and macrophages, MSP/RON signaling can function as a negative regulator of nitric oxide (NO) production (46) . MSP is capable of blocking the increase in macrophage inducible nitric oxide synthase mRNA and its associated increase in the production of NO in response to stimuli, including lipopolysaccharide (LPS) (47) .
The ability of sHepsin to generate MSP that actively suppresses NO production was examined in a cell culture system in which primary mouse bone marrow macrophages were exposed to LPS. Exposure to LPS resulted in a dramatic increase in macrophage NO production as measured by nitrite concentration in medium, whereas this response remained unchanged by the addition of pro-MSP alone (Fig. 4B) . However, the addition of sHepsin to pro-MSP in the culture medium led to a significant attenuation of NO production, comparable to the effect by mature MSP from a commercial source (Fig. 4B) and in agreement with the approximately 50% reduction (p<0.0002) of NO production by MSP reported in the literature (11) . Inhibition of sHepsin by Ab25 reversed NO production back to control levels, suggesting that reduction of NO synthesis was entirely mediated by sHepsin-dependent activation of pro-MSP.
Gene expression profiles of MSP and hepsin in comparison to HGFA and MT-SP1
Tissue distribution of MSP expression in normal and disease tissues (Fig. 5A) showed that MSP is expressed most highly in liver, followed by kidney, pancreas, and (Fig. 5A ) revealed a similar tissue distribution for hepsin, which was also highly expressed in liver, kidney, and pancreas, but not in small intestine. HGFA was also expressed at highest levels in liver, but not in other tissues, while MT-SP1 and RON were expressed predominantly in colorectal, small intestine, and stomach samples.
To evaluate these gene expression relationships in more detail, we generated scatter plots of MSP expression against that of the other genes in the liver, kidney, pancreas, and small intestine (Fig. 5B) . These scatter plots showed a strong correlation of expression between MSP and hepsin among normal and disease samples of kidney, liver, and pancreas, but not of small intestine. Co-expression was also observed between MSP and HGFA in liver samples, and between MSP and both MT-SP1 and RON in small intestinal samples. 
In addition to pro-MSP, hepsin was shown to activate pro-HGF and pro-uPA, and to cleave laminin-332 (19, 34, 36) . The hepsin-mediated processing of these substrates activates enzymatic cascades and/or initiates biological pathways that pertain to tumor growth and progression. Hepsin-activated pro-uPA activates plasminogen to plasmin, which then degrades extracellular matrix proteins directly or indirectly by activating latent forms of matrix metalloproteases (49, 50) . Degradation of stromal and basement membranes are critical for tumors to invade and metastasize, and it constitutes a hallmark for increased tumor aggressiveness. Similarly, hepsin enzymatic activity towards the basement membrane constituent laminin-332, which generates pro-migratory laminin-332 fragments, as well as the hepsin-mediated activation of the HGF/Met and MSP/RON signaling pathways, may promote tumor invasion and progression. For instance, hepsin is highly upregulated in prostate cancer epithelial cells (20, 28) , which also express RON (51, 52) . RON was found to regulate the production of angiogenic chemokines promoting tumor growth and angiogenesis (52, 53) . Therefore, the increased expression of hepsin in prostate cancer could activate RON-dependent signaling in cancer cells to promote cancer progression. In vivo studies using mouse prostate tumor models support a role of hepsin in basement membrane degradation and in tumor invasion and metastasis (28, 29) .
The plasminogen-like growth factors MSP and HGF share the same domain architecture and activation mechanism, and initiate intracellular signaling pathways that lead to proliferation, migration and differentiation (Fig. 6) . The fact that the single-chain precursors, pro-HGF and pro-MSP, have no biological activity strongly suggests that the activating proteases are critical in regulating the MSP/RON and HGF/Met pathways. It is intriguing that both pro-MSP and pro-HGF are activated by the three trypsin-like serine proteases hepsin, MT-SP1, and HGFA and that all three proteases are inhibited by the same two Kunitz domain inhibitors, HAI-1 and HAI-2 (40, 41, 54) (Fig. 6 ). This could mean that they are components of the same biological systems involving growth factor mediated cellular responses, such as tissue repair and tumorigenesis. Given the assumption that latent growth factors are abundantly present in the extracellular space Recently, gene expression profiling used to identify MT-SP1 as a pro-MSP activator showed that both MSP and MT-SP1 expression correlated in normal and disease tissues (11) . In this report, we detected a strong correlation of MSP expression with hepsin expression in the liver, kidney and pancreas that was superior to the corresponding correlations observed between MSP and HGFA or MSP and MT-SP1. Both hepsin and MSP are produced by hepatocytes in the liver (58, 59) and renal tubule cells in the kidney (58, 60) , which were recently shown to increase MSP production during the regenerative phase in a mouse renal injury model (60) . In light of the potent pro-MSP convertase activity for hepsin in vitro, the co-expression results suggest that hepsin may regulate pro-MSP activation in tissue homeostasis or after tissue injury. The biochemical linkage between hepsin with the MSP/RON system presented in this study is likely to form the basis for further investigations directed at understanding the biological regulation of the MSP/RON pathway by proteases under normal and patho-physiological conditions. Table 1 .
Hepsin substrates
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